Semaglutide for Weight Loss Cost in Iowa

Semaglutide for Weight Loss in Iowa costs $187 to $1,316 in 2026, with a state-wide median of $329. Pricing varies by metro - typically $329 in Des Moines and $329 in Des Moines. Iowa pricing is 6% below the national average.

Des Moines typically has the lowest semaglutide for weight loss pricing in Iowa, with a median of $329 (0.94x national average). Mid-size markets generally run lower than major coastal or wealthy suburban areas.

Des Moines typically has the highest semaglutide for weight loss pricing in Iowa, with a median of $329 (0.94x national average). Larger metro areas with higher cost of living and more specialty providers tend to command premium pricing.

Insurance coverage for semaglutide varies dramatically by plan, employer, and indication. Wegovy (branded for obesity) is covered by many commercial plans with prior authorization requiring documented BMI 30+ or 27+ with comorbidities. Medicare currently does not cover any obesity medication, including Wegovy. Ozempic (branded for diabetes) is broadly covered for type 2 diabetes patients. Compounded versions are generally not covered.

Iowa pricing is 6% below the national average. The state cost index is 0.94x the national average. Higher-cost states include California, New York, Massachusetts, and Washington DC; lower-cost states include Oklahoma, Mississippi, Kentucky, and Indiana.

Brand-name Wegovy retails at approximately $1,300 per month without insurance in 2026. Compounded semaglutide from licensed 503A pharmacies through telehealth weight-loss clinics typically runs $199 to $499 per month, a 60 to 85 percent discount. With insurance coverage for Wegovy, out-of-pocket can be $0 to $50 with prior authorization. Medicare does not cover for obesity but does cover Ozempic for type 2 diabetes.

Published clinical trials show average weight loss of 12 to 17 percent of starting body weight at 68 weeks on the maximum dose (2.4 mg/week). For a 220-pound starting weight, that is approximately 26 to 37 pounds. Results vary significantly: some patients lose 25+ percent, others lose under 5 percent. Roughly 85 percent of patients achieve at least 5 percent weight loss; about 50 percent achieve at least 15 percent.

Compounded semaglutide from licensed 503A pharmacies using FDA-approved active pharmaceutical ingredients is widely considered safe by clinicians, though it carries less manufacturing oversight than brand-name Wegovy. Risks include variable potency, contamination, and use of unapproved "salt forms" (semaglutide acetate or sodium) by lower-quality compounders. Verify your clinic uses an FDA-registered 503A pharmacy and asks about API source. Avoid pharmacies that cannot provide certificate of analysis.

Studies show 60 to 70 percent of weight lost on semaglutide is regained within 12 to 24 months of stopping. Most patients require ongoing maintenance dosing (often at reduced dose) to maintain weight loss long-term, or robust lifestyle changes including resistance training, structured nutrition, and behavioral support. Semaglutide is generally considered a long-term or indefinite medication for chronic weight management, similar to medications for high blood pressure or diabetes.

The most common side effects are gastrointestinal: nausea (30-45 percent), constipation (20-30 percent), diarrhea (15-25 percent), and vomiting (15-25 percent). Side effects are typically mild to moderate and most pronounced during dose increases, then subside over 1-2 weeks at each dose level. Rare but serious side effects include gallbladder disease (1-2 percent), pancreatitis (less than 0.5 percent), and theoretical risk of thyroid C-cell tumors (not confirmed in humans).